抗EBV BNLF2b抗体在疑似鼻咽癌中的诊断性能
该前瞻性多中心队列研究纳入3777例临床疑似鼻咽癌的门诊患者,头对头比较P85-Ab与VCA-IgA、EA-IgA、EBNA1-IgA的诊断性能。P85-Ab灵敏度93.0%、特异度97.3%,在无症状及鼻咽癌非特异症状人群中保持高灵敏度;鼻咽癌特异症状人群中三联抗体策略灵敏度优于单用P85-Ab。
要点
- P85-Ab诊断疑似鼻咽癌灵敏度93.0%、特异度97.3%,优于其他EBV抗体。
- 无症状及非特异症状人群单用P85-Ab即可,三联抗体无额外获益。
- 鼻咽癌特异症状人群三联抗体策略灵敏度95.9%,优于单用P85-Ab的93.1%。
核心结论
- P85-Ab是门诊疑似鼻咽癌的稳健且准确的生物标志物。
- 无症状或鼻咽癌非特异症状人群可建议单用P85-Ab。
- 鼻咽癌特异症状人群可建议P85-Ab联合VCA-IgA和EBNA1-IgA。
研究设计与样本
- 前瞻性多中心队列研究,2021年4月至2024年3月在中国5个医疗中心门诊开展,中位随访27.2个月。
- 连续纳入3795例临床疑似鼻咽癌参与者,排除低质量样本或失访后,3777例纳入最终分析(鼻咽癌1680例,非鼻咽癌2097例)。
- P85-Ab采用化学发光免疫分析法检测,VCA-IgA、EA-IgA和EBNA1-IgA采用酶联免疫吸附试验检测。
主要发现
- 3777例参与者中位年龄49.0岁(IQR 37.0-58.0),男性占65%。
- P85-Ab灵敏度93.0%(95% CI 91.6-94.0),特异度97.3%(95% CI 96.5-97.9)。
- 其他生物标志物灵敏度较低(范围60.4%至93.0%),特异度均低于90%。
- P85-Ab在无症状人群中灵敏度92.0%(95% CI 85.9-95.6),在鼻咽癌非特异症状人群中灵敏度88.4%(95% CI 75.5-94.9)。
- 鼻咽癌特异症状人群中,三联抗体策略灵敏度95.9%(95% CI 94.8-96.8),优于单用P85-Ab的93.1%(95% CI 91.7-94.3),P < .001。
关键数值与推荐
- P85-Ab单用:灵敏度93.0%(95% CI 91.6-94.0),特异度97.3%(95% CI 96.5-97.9)。
- 无症状人群P85-Ab灵敏度92.0%(95% CI 85.9-95.6)。
- 鼻咽癌非特异症状人群P85-Ab灵敏度88.4%(95% CI 75.5-94.9)。
- 鼻咽癌特异症状人群三联抗体策略灵敏度95.9%(95% CI 94.8-96.8),单用P85-Ab为93.1%(95% CI 91.7-94.3),P < .001。
- P85-Ab联合VCA-IgA和EBNA1-IgA在无症状及非特异症状人群中未观察到额外诊断获益。
临床怎么用
- 门诊疑似鼻咽癌患者可优先检测P85-Ab以提高诊断准确性。
- 无症状或鼻咽癌非特异症状人群可单用P85-Ab进行筛查或诊断评估。
- 鼻咽癌特异症状人群可考虑P85-Ab联合VCA-IgA和EBNA1-IgA检测以提高灵敏度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It remains uncertain which Epstein-Barr virus (EBV)-related biomarkers provide the most reliable diagnostic performance for suspected nasopharyngeal carcinoma (NPC) in outpatient settings, especially regarding the novel anti-EBV BNLF2b total antibody (P85-Ab) assay. Clarifying their accuracy is critical to improving early detection and reducing misdiagnosis. OBJECTIVE: To evaluate the diagnostic performance of the P85-Ab assay in suspected NPC in outpatient settings and compare it head-to-head with EBV viral capsid antigen (VCA)-immunoglobulin A (IgA), EBV early antigen (EA)-IgA, and EBV nuclear antigen 1 (EBNA1)-IgA. DESIGN, SETTING, AND PARTICIPANTS: A prospective, multicenter cohort study was conducted between April 2021 and March 2024, with a median follow-up of 27.2 months in outpatient clinics across 5 medical centers in China. Key inclusion criteria comprised clinically suspected NPC. Data were analyzed from June 2025 to July 2025. EXPOSURES: P85-Ab was tested using chemiluminescent immunoassay. VCA-IgA, EA-IgA, and EBNA1-IgA were tested via enzyme-linked immunosorbent assays. MAIN OUTCOMES AND MEASURE: Primary outcomes included sensitivity and specificity of P85-Ab. RESULTS: A total of 3795 eligible participants were consecutively recruited. After excluding individuals with low-quality samples or lost to follow-up, 3777 participants were included in the final analysis (1680 with NPC and 2097 without NPC). Among the 3777 evaluated participants (median [IQR] age, 49.0 [37.0-58.0] years; 65 % male), P85-Ab demonstrated superior diagnostic performance, with a sensitivity of 93.0% (95% CI, 91.6-94.0) and specificity of 97.3% (95% CI, 96.5-97.9). Other biomarkers showed lower sensitivity (ranging from 60.4% to 93.0%) and specificity (<90%). P85-Ab maintained high sensitivity among asymptomatic individuals (92.0%; 95% CI, 85.9-95.6) and those presenting with NPC-nonspecific symptoms (88.4%; 95% CI, 75.5-94.9), with no additional diagnostic benefit observed from the triplet-antibody strategy combining P85-Ab, VCA-IgA, and EBNA1-IgA. However, among participants with NPC-specific symptoms, the triplet-antibody strategy improved sensitivity compared with P85-Ab alone (95.9%; 95% CI, 94.8-96.8 vs 93.1%; 95% CI, 91.7-94.3; P < .001). CONCLUSIONS AND RELEVANCE: In this cohort study, P85-Ab was a robust and accurate biomarker for suspected NPC in outpatient settings. P85-Ab alone may be suggested for populations with asymptomatic or NPC-nonspecific symptoms, and combining P85-Ab with VCA-IgA and EBNA1-IgA may be suggested for populations with NPC-specific symptoms.
引用
- Li SC, Li FG, Wu SJ, et al. Diagnostic Performance of Anti-Epstein-Barr Virus BNLF2b in Suspected Nasopharyngeal Carcinoma. JAMA Oncol. 2026. PMID: 41854586. doi:10.1001/jamaoncol.2026.0251
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。